Send to

Choose Destination
See comment in PubMed Commons below
Rev Urol. 2007 Fall;9(4):207-13.

Newer potential biomarkers in prostate cancer.

Author information

Department of Urology, University of Washington School of Medicine Seattle, WA.


Prostate-specific antigen (PSA) screening has led to a significant rise in the number of men diagnosed with prostate cancer and an associated increase in biopsies performed. Despite its limitations, including a positive predictive value of only 25%-40%, PSA remains the only generally accepted biomarker for prostate cancer. There is a need for better tools to not only identify men with prostate cancer, but also to recognize those with potentially lethal disease who will benefit from intervention. A great deal of work has been done worldwide to improve our knowledge of the genetics behind prostate cancer and the specificity of PSA by developing assays for different PSA isoforms. Common genetic alterations in prostate cancer patients have been identified, including CpG hypermethylation of GSPT1 and TMPRSS2:ERG gene fusion. Serum and urine detection of RNA biomarkers (eg, PCA3) and prostate cancer tissue protein antibodies (eg, EPCA) are being evaluated for detection and prognostic tools. This article reviews some of the promising developments in biomarkers.


Alpha-methylacyl CoA racemase; Autoantibody arrays; DNA biomarkers; Epigenetic markers; Gene fusion proteins; Heterozygosity; Human kallikreins; PCA3; PSA isoforms; Prostate-specific antigen; RNA biomarkers

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center